BCPC — BALCHEM CORP
Public company
Sign in to save2 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
About BALCHEM CORP (BCPC)
BALCHEM CORP (BCPC) appears in the most recent 13F filings of 2 tracked institutional investors. The largest disclosed position is held by Ray Dalio (Bridgewater Associates), valued at $3M. Across recent filings, tracked investors recorded 2 new positions, 1 increased, 1 reduced, and 0 exited. All data sourced from SEC 13F filings.
Tracked investors reporting BCPC
- Ray DalioMar 31, 2026Bridgewater AssociatesShares17.3KValue$2.9M% Portfolio0.01%
- Ken GriffinDec 31, 2025Citadel AdvisorsShares23.5KValue$3.6K% Portfolio0.00%
Recent activity
- Increased$2.9M(260.24%)May 15, 2026
- Reduced$3.6K(-62.03%)Feb 17, 2026
- New$737Feb 13, 2026
- New$9.3KNov 14, 2025
Frequently asked questions
- How many institutional investors hold BCPC?
- 2 tracked institutional investors disclosed a position in BCPC (BALCHEM CORP) in their most recent 13F filing.
- Who is the largest institutional holder of BCPC?
- Ray Dalio, Bridgewater Associates, holds the largest disclosed position in BCPC, valued at $3M.
- Did institutional ownership of BCPC increase or decrease?
- Across recent 13F filings, tracked investors recorded 2 new positions, 1 increased, 1 reduced, and 0 fully exited BCPC.
- Where does this BCPC ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.